Financial Results for the Financial Year ended 31/03/2026
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma reported total revenue of Rs 77,601.30 Lakhs for FY26, up 15.6% from Rs 67,097.02 Lakhs in FY25, driven by growth in revenue from operations to Rs 77,165.74 Lakhs. However, profit after tax declined 13.3% to Rs 4,104.61 Lakhs from Rs 4,735.19 Lakhs, impacted by rising cost of materials (Rs 51,044.32 Lakhs vs Rs 46,327.71 Lakhs) and increased other expenses. EBITDA margin compressed from 10.64% to 8.56%. The company issued bonus shares in 1:1 ratio during the year. Statutory auditors issued an unmodified opinion. Operating cash flow turned negative at Rs -301.16 Lakhs (vs +Rs 3,712.47 Lakhs in FY25) due to significant inventory buildup of Rs 7,327.41 Lakhs.
Revenue growth was offset by cost pressures and margin compression; PAT decline and negative operating cash flow are concerning signals for shareholders despite the unqualified audit opinion.